People · Operator

Mark Poff

Named in public records as an officer, director or promoter · active 2009–2009 · Other

1
Companies
1
Filings
$102.9M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Insight Pharmaceuticals CorpOtherSeries C$102.9M$1.1B2009
Operator network

Mark Poff at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Daniel C. Reese · 7 companies · 1 sharedDaniel C. ReeseRobert Monk · 5 companies · 1 sharedRobert MonkC. Morris Stout · 3 companies · 1 sharedC. Morris StoutScott C. Emerson · 2 companies · 1 sharedScott C. EmersonCraig Hille · 1 companies · 1 sharedCraig HilleDennis Kinsey · 1 companies · 1 sharedDennis KinseyGary Downing · 1 companies · 1 sharedGary DowningJames Berwick · 1 companies · 1 sharedJames BerwickJoseph Suprenuk · 1 companies · 1 sharedJoseph SuprenukKipp C. DeVeer · 1 companies · 1 sharedKipp C. DeVeerKipp DeVeer · 1 companies · 1 sharedKipp DeVeerMark C. Poff · 1 companies · 1 sharedMark C. PoffMichael C. Smith · 1 companies · 1 sharedMichael C. SmithMichael C. Westhusing · 1 companies · 1 sharedMichael C. Westhu…Mickael Tukdarian · 1 companies · 1 sharedMickael TukdarianInsight Pharmaceuticals Corp · $102.9M raisedInsight Pharmaceutica…Mark PoffMP
Mark Poff Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Mark Poff on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Daniel C. Reese17
Robert Monk15
C. Morris Stout13
Scott C. Emerson12
Mark C. Poff11
Mickael Tukdarian11
Michael C. Smith11
Michael C. Westhusing11
Kipp C. DeVeer11
Kipp DeVeer11
Craig Hille11
Joseph Suprenuk11
James Berwick11
Dennis Kinsey11
Gary Downing11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.